Effects of blood pressure reduction in mild XXXX : a systematic review and meta-analysis.

@entity1 @entity64 @entity712 @entity101 @entity6 @entity204 @entity65
BACKGROUND: Effects of blood pressure reduction in @entity1 with grade 1 @entity101 are unclear. PURPOSE: To investigate whether pharmacologic blood pressure reduction prevents @entity65 and @entity204 in @entity1 with grade 1 @entity101 . DATA SOURCES: Trials included in the BPLTTC (Blood Pressure Lowering Treatment Trialists' Collaboration) and trials identified from a previous review and electronic database searches. STUDY SELECTION: @entity1 without @entity65 with blood pressures in the grade 1 @entity101 range (140 to 159/90 to 99 mm Hg) who were randomly assigned to an active (antihypertensive drug or more intensive regimen) or control (placebo or less intensive regimen) blood pressure-lowering regimen. DATA EXTRACTION: Individual- @entity1 data from BPLTTC trials and aggregate data from other trials were extracted. Risk of bias was assessed for all trials. DATA SYNTHESIS: Individual- @entity1 data involved 10 comparisons from trials where most @entity1 had @entity6 , and aggregate data involved 3 comparisons from trials of @entity1 without @entity6 . The average blood pressure reduction was about 3.6/2.4 mm Hg. Over 5 years, odds ratios were 0.86 (95% CI, 0.74 to 1.01) for total @entity65 , 0.72 (CI, 0.55 to 0.94) for @entity64 , 0.91 (CI, 0.74 to 1.12) for coronary events, 0.80 (CI, 0.57 to 1.12) for @entity712 , 0.75 (CI, 0.57 to 0.98) for @entity65 , and 0.78 (CI, 0.67 to 0.92) for total @entity204 . Results were similar in secondary analyses. Withdrawal from treatment due to adverse effects was more common in the active groups. LIMITATION: Blood pressure reductions and numbers of events were small. CONCLUSION: Blood pressure-lowering therapy is likely to prevent @entity64 and @entity204 in @entity1 with uncomplicated grade 1 @entity101 . PRIMARY FUNDING SOURCE: Swedish Heart-Lung Foundation, Swedish Research Council, Australian Research Council, and National Health and Medical Research Council of Australia.
